Please ensure Javascript is enabled for purposes of website accessibility
Cory Renauer

Cory Renauer


Cory is a long-term minded analyst focused on the Healthcare Sector. He genuinely enjoys cutting through the complexity to help everyday investors make better decisions.

Recent articles


Why 180 Life Sciences Stock Is Falling Today

Another capital raise less than a year after the company's stock market debut is more than a little troubling.


2 Beaten-Down Biotech Stocks: Are They Bargains Now?

These drugmakers delivered some upsetting news, but was it really so bad?

life science smile getty

Here's Why Travere Therapeutics Stock Is Climbing Today

Investors are cheering positive phase 3 trial results with sparsentan that suggest it could become an important new treatment for a rare kidney disease.


3 Life Science Stocks Cathie Wood's Buying Hand Over Fist Right Now

ARK Invest made multiple purchases of these stocks last week.


Why SmileDirectClub Stock Is Falling 24% This Week

Second-quarter earnings show the company's competition with Align Technology has gone completely lopsided.


Why LifeStance Health Group Stock Is Crashing Today

The mental health service provider surprised investors with heavy operating losses.


Why Fulcrum Therapeutics Popped Again on Tuesday

Compelling clinical-trial data that could validate the company's unique approach to new drug development inspired a slew of analyst upgrades.


Here's Why Doximity Stock Is Surging Today

The networking platform for healthcare professionals keeps exceeding expectations.


3 of the Best Stocks You Can Buy With $200 or Less

These three giants of the healthcare sector aren't too big to buy with just a couple hundred bucks.


Here's Why Fulcrum Therapeutics Stock Is Shooting Higher Today

A positive trial readout suggests the company's new drug discovery engine has more potential than expected.


Why Elanco Animal Health Stock Is Falling Today

A downward guidance revision for 2021 earnings is overshadowing impressive sales growth.


Zymergen's Implosion Makes Amyris a Screaming Buy

The flashy synthetic-biology start-up ran into a wall that Amyris has already learned how to climb over.


Why Dicerna Pharmaceuticals Stock Is Tumbling on Friday

A less than satisfying result from a phase 2 trial with nedosiran makes the company's future difficult to predict.


Why Aurinia Pharmaceuticals Stock Was Surging on Friday

Investors were relieved to see significant sales from the company's first commercial-stage drug.


Why BioCryst Pharmaceuticals Rose 8% on Thursday

The company's first commercial drug launch keeps exceeding expectations.


Here's Why Ampio Pharmaceuticals Stock Is Surging Today

A positive second-quarter earnings report and anticipation of further details to be discussed this afternoon helped this beaten-down biotech stock recover some previous losses.


3 Unstoppable Healthcare Stocks to Buy Now and Hold Forever

Here are some terrific options for investors who just want to set it and forget it.


3 High-Growth Healthcare Stocks to Buy in August

These potential stock rockets are well worth the different risks they present.


Here's Why TG Therapeutics Stock Is Getting Hammered Today

A second-quarter earnings report reminded investors how difficult it is for independent companies to launch new cancer drugs.


Here's Why Autolus Therapeutics Is Surging Today

Potential licensing agreements with Moderna are giving investors reasons to cheer.